- $99.56m
- $40.32m
- $237.26m
Brief: Vaxart Announces Initiation Of Sentinel Cohort For Phase 2B Study Evaluating Its Covid-19 Oral Pill Vaccine Candidate
Brief: Vaxart Announces Publication In Vaccines Of Preclinical Data
U.S. RESEARCH ROUNDUP-Allstate, Bluebird Bio, Vicinity Motor
Vaxart Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vaxart Q2 Net Income USD -16.466 Million
Vaxart Inc expected to post a loss of 3 cents a share - Earnings Preview
Vaxart Inc expected to post a loss of 3 cents a share - Earnings Preview
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet (updated)
Brief: Vaxart Says Cash Runway Extended Into 2026
Brief: Vaxart Says $40 Million Underwritten Offering Of Common Stock
Brief: Vaxart Receives Barda-Funded Award Valued Up To $453 Mln For A Phase 2B Study On Covid-19 Oral Pill Vaccine Candidate
US government to fund up to $500 mln for studies on oral, nasal COVID vaccines
Vaxart Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vaxart Q1 Net Income USD -24.417 Million
Vaxart Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Vaxart Long-Term Goal Is To Protect Infants Through Passive Antibody Transfer
Vaxart Inc expected to post a loss of 14 cents a share - Earnings Preview
Vaxart Inc reports results for the quarter ended in December - Earnings Summary
Vaxart Inc expected to post a loss of 14 cents a share - Earnings Preview